150 related articles for article (PubMed ID: 37852029)
1. Interactions between nanoparticle corona proteins and the immune system.
Tran TT; Roffler SR
Curr Opin Biotechnol; 2023 Dec; 84():103010. PubMed ID: 37852029
[TBL] [Abstract][Full Text] [Related]
2. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
[TBL] [Abstract][Full Text] [Related]
3. Protein corona: a new approach for nanomedicine design.
Nguyen VH; Lee BJ
Int J Nanomedicine; 2017; 12():3137-3151. PubMed ID: 28458536
[TBL] [Abstract][Full Text] [Related]
4. The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine.
Cai R; Chen C
Adv Mater; 2019 Nov; 31(45):e1805740. PubMed ID: 30589115
[TBL] [Abstract][Full Text] [Related]
5. Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses.
Shen L; Tenzer S; Storck W; Hobernik D; Raker VK; Fischer K; Decker S; Dzionek A; Krauthäuser S; Diken M; Nikolaev A; Maxeiner J; Schuster P; Kappel C; Verschoor A; Schild H; Grabbe S; Bros M
J Allergy Clin Immunol; 2018 Nov; 142(5):1558-1570. PubMed ID: 29382591
[TBL] [Abstract][Full Text] [Related]
6. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.
Corbo C; Molinaro R; Parodi A; Toledano Furman NE; Salvatore F; Tasciotti E
Nanomedicine (Lond); 2016 Jan; 11(1):81-100. PubMed ID: 26653875
[TBL] [Abstract][Full Text] [Related]
7. The effect of drug loading and multiple administration on the protein corona formation and brain delivery property of PEG-PLA nanoparticles.
Tang Y; Gao J; Wang T; Zhang Q; Wang A; Huang M; Yu R; Chen H; Gao X
Acta Pharm Sin B; 2022 Apr; 12(4):2043-2056. PubMed ID: 35847504
[TBL] [Abstract][Full Text] [Related]
8. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
9. Insights into colloidal nanoparticle-protein corona interactions for nanomedicine applications.
Martínez-Negro M; González-Rubio G; Aicart E; Landfester K; Guerrero-Martínez A; Junquera E
Adv Colloid Interface Sci; 2021 Mar; 289():102366. PubMed ID: 33540289
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System.
Perciani CT; Liu LY; Wood L; MacParland SA
ACS Nano; 2021 Jan; 15(1):7-20. PubMed ID: 33346646
[TBL] [Abstract][Full Text] [Related]
11. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.
Cruz LJ; Tacken PJ; Fokkink R; Figdor CG
Biomaterials; 2011 Oct; 32(28):6791-803. PubMed ID: 21724247
[TBL] [Abstract][Full Text] [Related]
12. Delivery and short-term maternal and fetal safety of vaginally administered PEG-PLGA nanoparticles.
Irvin-Choy NS; Nelson KM; Gleghorn JP; Day ES
Drug Deliv Transl Res; 2023 Dec; 13(12):3003-3013. PubMed ID: 37365402
[TBL] [Abstract][Full Text] [Related]
13. Influence of nanoparticle mechanical property on protein corona formation.
Tengjisi ; Hui Y; Fan Y; Zou D; Talbo GH; Yang G; Zhao CX
J Colloid Interface Sci; 2022 Jan; 606(Pt 2):1737-1744. PubMed ID: 34507167
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol modulates the physiological response to nanoparticles by changing the composition of protein corona.
Tang H; Zhang Y; Yang T; Wang C; Zhu Y; Qiu L; Liu J; Song Y; Zhou L; Zhang J; Wong YK; Liu Y; Xu C; Wang H; Wang J
Nat Nanotechnol; 2023 Sep; 18(9):1067-1077. PubMed ID: 37537273
[TBL] [Abstract][Full Text] [Related]
15. Effects of engineered nanoparticles on the innate immune system.
Liu Y; Hardie J; Zhang X; Rotello VM
Semin Immunol; 2017 Dec; 34():25-32. PubMed ID: 28985993
[TBL] [Abstract][Full Text] [Related]
16. Formation of the Protein Corona: The Interface between Nanoparticles and the Immune System.
Barbero F; Russo L; Vitali M; Piella J; Salvo I; Borrajo ML; Busquets-Fité M; Grandori R; Bastús NG; Casals E; Puntes V
Semin Immunol; 2017 Dec; 34():52-60. PubMed ID: 29066063
[TBL] [Abstract][Full Text] [Related]
17. Interactions of Apolipoproteins with Lipid-Based Nanoparticles.
Dalhaimer P; Florey B; Isaac S
ACS Nano; 2023 Jan; ():. PubMed ID: 36622840
[TBL] [Abstract][Full Text] [Related]
18. How protein coronas determine the fate of engineered nanoparticles in biological environment.
Capjak I; Goreta SŠ; Jurašin DD; Vrček IV
Arh Hig Rada Toksikol; 2017 Dec; 68(4):245-253. PubMed ID: 29337683
[TBL] [Abstract][Full Text] [Related]
19. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo.
Grenier P; Viana IMO; Lima EM; Bertrand N
J Control Release; 2018 Oct; 287():121-131. PubMed ID: 30138715
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine strategy for optimizing delivery to outer hair cells by surface-modified poly(lactic/glycolic acid) nanoparticles with hydrophilic molecules.
Wen X; Ding S; Cai H; Wang J; Wen L; Yang F; Chen G
Int J Nanomedicine; 2016; 11():5959-5969. PubMed ID: 27877041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
